Quick Answer
LIGAND PHARMACEUTICALS INC reported Total Assets of $1.56 billion for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +65.7% in Total Assets from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $127.44 million | Q3 2011: $122.47 million | Q1 2012: $111.80 million | Q2 2012: $104.59 million | Q3 2012: $97.51 million | Q1 2013: $98.36 million | Q2 2013: $99.57 million | Q3 2013: $101.68 million | Q1 2014: $105.47 million | Q2 2014: $99.85 million | Q3 2014: $272.28 million | Q1 2015: $263.22 million | Q2 2015: $304.76 million | Q3 2015: $496.33 million | Q1 2016: $613.44 million | Q2 2016: $616.80 million | Q3 2016: $600.87 million | Q1 2017: $629.72 million | Q2 2017: $640.02 million | Q3 2017: $662.34 million | Q1 2018: $754.67 million | Q2 2018: $1.86 billion | Q3 2018: $2.11 billion | Q1 2019: $1.91 billion | Q2 2019: $1.80 billion | Q3 2019: $1.55 billion | Q1 2020: $1.19 billion | Q2 2020: $1.24 billion | Q3 2020: $1.25 billion | Q1 2021: $1.30 billion | Q2 2021: $1.26 billion | Q3 2021: $1.27 billion | Q1 2022: $1.11 billion | Q2 2022: $1.08 billion | Q3 2022: $1.05 billion | Q1 2023: $811.08 million | Q2 2023: $758.11 million | Q3 2023: $769.23 million | Q1 2024: $913.87 million | Q2 2024: $866.41 million | Q3 2024: $954.87 million | Q1 2025: $905.44 million | Q2 2025: $948.60 million | Q3 2025: $1.48 billion.
- Over the full 16 years of available data (2010 to 2025), LIGAND PHARMACEUTICALS INC's Total Assets has grown by 1,965.5%.
- Historical annual values: Fiscal year 2025: $1.56 billion | Fiscal year 2024: $941.77 million | Fiscal year 2023: $787.22 million | Fiscal year 2022: $762.67 million | Fiscal year 2021: $1.30 billion | Fiscal year 2020: $1.36 billion | Fiscal year 2019: $1.49 billion | Fiscal year 2018: $1.26 billion | Fiscal year 2017: $671.02 million | Fiscal year 2016: $601.59 million | Fiscal year 2015: $503.06 million | Fiscal year 2014: $258.03 million | Fiscal year 2013: $104.71 million | Fiscal year 2012: $104.26 million | Fiscal year 2011: $120.58 million | Fiscal year 2010: $75.56 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: